A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

NCT02196324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis

Interventions

DRUG: serlopitant
DRUG: Placebo

Sponsor

Vyne Therapeutics Inc.